טוען...

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study

The treatment efficacy of advanced breast cancer is still not promising. This study aimed to compare the efficacy and safety of docetaxel/S-1 (DS1) versus docetaxel/capecitabine (DX) as the first-line treatment for advanced breast cancer. From June 2008 to June 2013, 22 patients with advanced breast...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Medicine (Baltimore)
Main Authors: Li, Jinyu, You, Junhao, Si, Wen, Zhu, Yanyun, Chen, Yi, Yang, Bo, Han, Chun, Linghu, Ruixia, Zhang, Xingyang, Jiao, Shunchang, Yang, Junlan
פורמט: Artigo
שפה:Inglês
יצא לאור: Wolters Kluwer Health 2015
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4616799/
https://ncbi.nlm.nih.gov/pubmed/26469889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000001340
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!